We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Innovation Fuels Rally for Tempus AI: Should You Buy the Stock Today?
Read MoreHide Full Article
Key Takeaways
TEM jumped 12.5% in early June, fueled by new product launches and strong investor response.
The $200M deal with AstraZeneca boosts TEM's role in AI-driven oncology diagnostics and drug discovery.
Despite revenue growth and tech advances, TEM remains unprofitable and trades at a premium to peers.
Tempus AI (TEM - Free Report) surged 12.5% in the first week of June, outperforming the broader market and the benchmarks by a wide margin. This rally came largely on the heels of investors’ positive reaction to two back-to-back innovations from the company. The first was the launch of xM, a new liquid biopsy assay for monitoring immunotherapy response in advanced cancer patients and the second was the EHR integration of Tempus One, the company’s generative AI-powered clinical assistant.
Given Tempus AI’s deep healthcare data infrastructure and rising clinical utility, investor optimism appears justified. Let's delve deeper into whether further upside is on the horizon or not.
Strategic Product Innovation
xM Liquid Biopsy Assay: The newly-launched xM is a liquid biopsy using whole-genome sequencing and fragmentomics to detect early molecular responses to immune checkpoint inhibitors (ICIs). It enables noninvasive, real-time treatment monitoring, which is especially valuable for advanced cancer patients.
Tempus One in EHRs: Tempus integrated its AI-powered voice assistant Tempus One into major EHR systems. This tool delivers real-time, patient-specific insights, trial options and guidelines to streamline workflows and enhance decision-making at the point of care.
$200 Million Foundation Model Partnership With AstraZeneca and Pathos
Tempus AI recently announced a landmark three-year, $200 million data and modeling license agreement with AstraZeneca (AZN - Free Report) and Pathos to develop the world’s largest oncology-focused foundation model. Leveraging over 300 petabytes of Tempus AI’s multimodal data, the initiative aims to accelerate AI-driven drug discovery and diagnostics. AstraZeneca, TEM’s first strategic biopharma partner, will play a central role in funding compute costs and co-developing the model alongside Pathos. Upon completion, each party will receive a copy of the model, strengthening Tempus AI’s position in precision medicine and expanding AstraZeneca’s oncology innovation capabilities. The deal also raises Tempus AI’s total remaining contract value to over $1 billion.
Deep 6 Acquisition Expands Clinical Connectivity and Data Assets
The acquisition of Deep 6 AI adds valuable clinical trial matching and provider analytics capabilities to Tempus AI’s portfolio. Deep 6’s platform strengthens Tempus AI’s provider connectivity, now totaling over 4,000 connections, and facilitates the two-way exchange of clinical and molecular data. This supports TEM’s goal of constructing rich, outcome-linked datasets that inform both diagnostics and drug development.
Year to date, TEM stock has skyrocketed 83.8%, outperforming the 24.3% rise of the Medical Info Systems industry and the Medical sector’s 2.7% decline. In the meantime, the S&P 500 has improved 2.1%. The company has also outperformed other players in the health infotech field, like iRhythm Technologies (IRTC - Free Report) and SOPHiA GENETICS (SOPH - Free Report) , which improved 62.6% and 1.9%, respectively, during the said period.
YTD Price Comparison of TEM
Image Source: Zacks Investment Research
TEM Ahead of Moving Averages Too
Going by the technical indicators, the stock is trading above its 50-day and 200-day moving averages, indicating upward momentum and price stability.
TEM Above the 50 and 200-day SMA
Image Source: Zacks Investment Research
Ongoing Losses Despite Revenue Growth
Tempus reported an adjusted EBITDA loss of $16.2 million in the first quarter of 2025, though it improved from a loss of $43.9 million in the first quarter of 2024. The company remains unprofitable despite record revenues and gross profit growth, highlighting the challenge of achieving profitability.
Is TEM Fairly Valued?
TEM stock is currently overvalued compared to its industry, as shown in the chart below.
The company is currently trading at a forward 12-month price-to-sales (P/S) ratio of 7.77, a premium to the broader industry's average of 6.09 and a little below the stock’s one-year median. The stock is also trading higher than other industry players like iRhythm (6.28X) and SOPHiA GENETICS (2.55X).
Image Source: Zacks Investment Research
Tempus AI is a "Hold" for Now
Tempus AI offers strong long-term potential fueled by genomics growth, expanding data services and a major AI partnership with AstraZeneca. However, this Zacks Rank #3 (Hold) stock trades at a premium to peers and faces stiff competition. The company is yet to deliver positive EBITDA or EPS. While macro trends like drug pricing reform aid, much of the optimism is already priced in. For now, current shareholders should hold their positions, while new investors should wait for a better entry point. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Innovation Fuels Rally for Tempus AI: Should You Buy the Stock Today?
Key Takeaways
Tempus AI (TEM - Free Report) surged 12.5% in the first week of June, outperforming the broader market and the benchmarks by a wide margin. This rally came largely on the heels of investors’ positive reaction to two back-to-back innovations from the company. The first was the launch of xM, a new liquid biopsy assay for monitoring immunotherapy response in advanced cancer patients and the second was the EHR integration of Tempus One, the company’s generative AI-powered clinical assistant.
Given Tempus AI’s deep healthcare data infrastructure and rising clinical utility, investor optimism appears justified. Let's delve deeper into whether further upside is on the horizon or not.
Strategic Product Innovation
xM Liquid Biopsy Assay: The newly-launched xM is a liquid biopsy using whole-genome sequencing and fragmentomics to detect early molecular responses to immune checkpoint inhibitors (ICIs). It enables noninvasive, real-time treatment monitoring, which is especially valuable for advanced cancer patients.
Tempus One in EHRs: Tempus integrated its AI-powered voice assistant Tempus One into major EHR systems. This tool delivers real-time, patient-specific insights, trial options and guidelines to streamline workflows and enhance decision-making at the point of care.
$200 Million Foundation Model Partnership With AstraZeneca and Pathos
Tempus AI recently announced a landmark three-year, $200 million data and modeling license agreement with AstraZeneca (AZN - Free Report) and Pathos to develop the world’s largest oncology-focused foundation model. Leveraging over 300 petabytes of Tempus AI’s multimodal data, the initiative aims to accelerate AI-driven drug discovery and diagnostics. AstraZeneca, TEM’s first strategic biopharma partner, will play a central role in funding compute costs and co-developing the model alongside Pathos. Upon completion, each party will receive a copy of the model, strengthening Tempus AI’s position in precision medicine and expanding AstraZeneca’s oncology innovation capabilities. The deal also raises Tempus AI’s total remaining contract value to over $1 billion.
Deep 6 Acquisition Expands Clinical Connectivity and Data Assets
The acquisition of Deep 6 AI adds valuable clinical trial matching and provider analytics capabilities to Tempus AI’s portfolio. Deep 6’s platform strengthens Tempus AI’s provider connectivity, now totaling over 4,000 connections, and facilitates the two-way exchange of clinical and molecular data. This supports TEM’s goal of constructing rich, outcome-linked datasets that inform both diagnostics and drug development.
Year to date, TEM stock has skyrocketed 83.8%, outperforming the 24.3% rise of the Medical Info Systems industry and the Medical sector’s 2.7% decline. In the meantime, the S&P 500 has improved 2.1%. The company has also outperformed other players in the health infotech field, like iRhythm Technologies (IRTC - Free Report) and SOPHiA GENETICS (SOPH - Free Report) , which improved 62.6% and 1.9%, respectively, during the said period.
YTD Price Comparison of TEM
Image Source: Zacks Investment Research
TEM Ahead of Moving Averages Too
Going by the technical indicators, the stock is trading above its 50-day and 200-day moving averages, indicating upward momentum and price stability.
TEM Above the 50 and 200-day SMA
Image Source: Zacks Investment Research
Ongoing Losses Despite Revenue Growth
Tempus reported an adjusted EBITDA loss of $16.2 million in the first quarter of 2025, though it improved from a loss of $43.9 million in the first quarter of 2024. The company remains unprofitable despite record revenues and gross profit growth, highlighting the challenge of achieving profitability.
Is TEM Fairly Valued?
TEM stock is currently overvalued compared to its industry, as shown in the chart below.
The company is currently trading at a forward 12-month price-to-sales (P/S) ratio of 7.77, a premium to the broader industry's average of 6.09 and a little below the stock’s one-year median. The stock is also trading higher than other industry players like iRhythm (6.28X) and SOPHiA GENETICS (2.55X).
Image Source: Zacks Investment Research
Tempus AI is a "Hold" for Now
Tempus AI offers strong long-term potential fueled by genomics growth, expanding data services and a major AI partnership with AstraZeneca. However, this Zacks Rank #3 (Hold) stock trades at a premium to peers and faces stiff competition. The company is yet to deliver positive EBITDA or EPS. While macro trends like drug pricing reform aid, much of the optimism is already priced in. For now, current shareholders should hold their positions, while new investors should wait for a better entry point. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.